Elena Sofer1, Marina Shargorodsky2,3. 1. Department of Medicine, Wolfson Medical Center, Tel Aviv, Israel. 2. Endocrinology, Wolfson Medical Center, Tel Aviv, Israel. marinas@wolfson.health.gov.il. 3. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. marinas@wolfson.health.gov.il.
Abstract
PURPOSE/ INTRODUCTION: Growing evidence suggests complex interplay between nonalcoholic fatty liver disease (NAFLD) and bone health. The present study's aim was to examine the impact of metformin treatment on circulating osteoprotegerin (OPG) in patients with NAFLD, a population in which this relationship has not yet been studied. METHODS: In a randomized, placebo-controlled study, 63 patients with NAFLD were assigned to one of two groups: Group 1 received daily metformin; Group 2 received a placebo. Metabolic parameters, insulin resistance markers and OPG levels were examined at baseline and at the end of the study. RESULTS: In the placebo group, liver function and OPG levels did not change during the study. Among metformin-treated patients, significant declines in OPG and alkaline phosphatase were observed. CRP and ALT decreased marginally during the 4-month treatment period. While at baseline circulating OPG levels did not differ significantly between the groups, by the end of the study OPG was significantly lower in patients treated with metformin than in the placebo group (p < 0.0001). Delta OPG was significantly greater in the metformin group than the placebo group (p = 0.001). In the general linear model, metformin treatment was the only significant independent predictor of endpoint and delta OPG. CONCLUSIONS: Metformin treatment was associated with a significant decrease in OPG levels in patients with NAFLD. The effect on OPG was associated with exposure to metformin per se. CLINICAL TRIAL REGISTRATION NUMBER: NCT01084486.
PURPOSE/ INTRODUCTION: Growing evidence suggests complex interplay between nonalcoholic fatty liver disease (NAFLD) and bone health. The present study's aim was to examine the impact of metformin treatment on circulating osteoprotegerin (OPG) in patients with NAFLD, a population in which this relationship has not yet been studied. METHODS: In a randomized, placebo-controlled study, 63 patients with NAFLD were assigned to one of two groups: Group 1 received daily metformin; Group 2 received a placebo. Metabolic parameters, insulin resistance markers and OPG levels were examined at baseline and at the end of the study. RESULTS: In the placebo group, liver function and OPG levels did not change during the study. Among metformin-treated patients, significant declines in OPG and alkaline phosphatase were observed. CRP and ALT decreased marginally during the 4-month treatment period. While at baseline circulating OPG levels did not differ significantly between the groups, by the end of the study OPG was significantly lower in patients treated with metformin than in the placebo group (p < 0.0001). Delta OPG was significantly greater in the metformin group than the placebo group (p = 0.001). In the general linear model, metformin treatment was the only significant independent predictor of endpoint and delta OPG. CONCLUSIONS: Metformin treatment was associated with a significant decrease in OPG levels in patients with NAFLD. The effect on OPG was associated with exposure to metformin per se. CLINICAL TRIAL REGISTRATION NUMBER: NCT01084486.
Authors: Elena Lima-Cabello; María Victoria García-Mediavilla; María E Miquilena-Colina; Javier Vargas-Castrillón; Tamara Lozano-Rodríguez; Miguel Fernández-Bermejo; José Luis Olcoz; Javier González-Gallego; Carmelo García-Monzón; Sonia Sánchez-Campos Journal: Clin Sci (Lond) Date: 2011-03 Impact factor: 6.124
Authors: Wing-Kin Syn; Steve S Choi; Evaggelia Liaskou; Gamze F Karaca; Kolade M Agboola; Ye Htun Oo; Zhiyong Mi; Thiago A Pereira; Marzena Zdanowicz; Padmini Malladi; Yuping Chen; Cynthia Moylan; Youngmi Jung; Syamal D Bhattacharya; Vanessa Teaberry; Alessia Omenetti; Manal F Abdelmalek; Cynthia D Guy; David H Adams; Paul C Kuo; Gregory A Michelotti; Peter F Whitington; Anna Mae Diehl Journal: Hepatology Date: 2010-10-21 Impact factor: 17.425